Abstract:Background: Increased HBV-replication and/or intracellular HBsAgretention favor the onset of hepatocellular-carcinoma (HCC).Here, we define mutations in pre-S1/Pre-S2/S-gene correlated with HBVinduced HCC in-vivo, and investigate their impact on HBsAgretention and secretion in an in-vitro model.Methods: Sixty-seven HBV chronically-infected patients (74.6% genotype-D; 20.9% genotype-A; and 4.5% others), 19 of them with HCC and 48 asymptomatic patients (as control), were analyzed.Association of mutations with HCC was assessed by Fisher-test with Benjamini-Hochberg for multiple-comparison correction.Mutants were constructed by site-directed mutagenesis and expressed in HuH7-hepatocytes using the expression-vectors pCHD9 with fulllength HBV-genome (for mutations S98T S1 -P203Q S -S210R S ) and pCHsAgD with pre-S1/pre-S2/S-gene (for N40I S -K141N S ).After 72h quantitative-HBsAg was tested in cell-supernatants and in celllysates using Abbott-Architect assay.Results: Novel mutations in pre-S1 (S98T S1 ), and S region (N40I S -K141N S -P203Q S -S210R S ) correlate with HCC (P = 10 -2 to 10 -4 ) invivo.19/19 patients with HCC carry ≥1 of them (range-prevalence: 12.5% to 37.5%), while these mutations are absent (0/48 for N40I S ) or occurring with low frequency (1.9% for K141N S -P203Q S , 4.7% for S98T S1, 7.5% for S210R S ) in non-HCC patients.Strong correlations are observed for P203Q S +S210R S (phi=0.83)and N40I S +K141N S (phi=0.56).S98T S1 corresponds to the nucleotide codon 3175-3177 of HBVgenome localized in the promoter of the middle S-protein.In in-vitro experiments, its presence determines a 3.71 foldincrease in HBsAg-levels released in supernatants (S98T: 127.47[sd±53.45]IU/ml;WT: 34.40[sd±13.28]IU/ml,P = 0.00016).An opposite scenario is observed for P203Q S +S210R S , localized in the membrane-embedded C-terminal domain critical for HBsAg-secretion.This couple of mutations drastically decreases supernatant HBsAg-levels compared to P203Q and S210R alone, and to wild-type (P203Q+S210R: 9.42[sd±1.35]IU/ml;P203Q: 26.85[sd±13.01]IU/ml;S210R: 25.95[sd±8.82]IU/ml;WT: 34.40[sd:±13.28]IU/ml,P < 0.01).P203Q+S210R also decrease the ratio of supernatant to lysate HBsAg compared to wild-type (0.61 for P203Q+S210R versus 1.20 for wild-type), supporting their ability in inducing HBsAg intracellular-retention.Similarly, K141N determines a 52%-reduction of supernatant HBsAglevels compared to wild-type (K141N: 13.43[sd±9.68]IU/ml;WT: 28.25[sd±13.12]IU/ml.This reduction is greater when K141N is co-present with N40I (K141N+N40I: 4.67[sd±2.31]IU/ml,P = 0.012).K141N introduces a new N-linked glycosylation-site, while N40I resides in the cytosolic-loop involved in HBsAg-secretion.Conclusions: Key genetic-elements in pre-S1/pre-S2/S-gene correlate with HCC by inducing intracellular HBsAg-retention and/or by potentially altering the production of mRNAs for S-gene.Their detection may help identifying patients at higher HCC-risk.

Hepatitis B surface antigen glycan isomer is a predictor of the development of hepatocellular carcinoma during nucleoside/nucleotide analog therapy

HBcrAgandpgRNAand the therapeutic effect inHBeAg-positive patients receiving anti-viral therapy, baseline serum HBV-RNAis a powerful predictor of response.

HBcrAg, Pg RNA and HBsAg Dynamically Supervise the Seroconversion of HBsAg with Anti-Viral Therapy "loss of HBsAg" Maybe Not a Good End-Point of Anti-Viral Therapy

Kinetics of serum O‐glycosylated M‐hepatitis B surface antigen with hepatocellular carcinoma history and nucleos(t)ide analogue therapy in hepatitis B patients

HBsAg as an important predictor of HBeAg seroconversion following antiviral treatment for HBeAg-positive chronic hepatitis B patients

Hepatitis B surface antigen (HBsAg) glycan isomer is predictive of HBsAg seroclearance in patients with chronic hepatitis B

Factors associated with low hepatitis B surface antigen levels in chronic hepatitis B patients treated with nucleot(s)ide analogs

Additional N-glycosylation mutation in the major hydrophilic region of hepatitis B virus S gene is a risk indicator for hepatocellular carcinoma occurrence in patients with coexistence of HBsAg/anti-HBs.

Baseline Quantitative Hepatitis B Core Antibody Titre Alone Strongly Predicts HBeAg Seroconversion Across Chronic Hepatitis B Patients Treated with Peginterferon or Nucleos(t)ide Analogues.

Role of early on-treatment serum HBV RNA declines in predicting hepatocellular carcinoma risk in patients with chronic hepatitis B

Level of hepatitis B surface antigen might serve as a new marker to predict hepatocellular carcinoma recurrence following curative resection in patients with low viral load.

Total Hepatitis B Core Antigen Antibody, a Quantitative Non-Invasive Marker of Hepatitis B Virus Induced Liver Disease

Coexistence of hepatitis B surface antigen and antibody to hepatitis B surface may increase the risk of hepatocellular carcinoma in chronic hepatitis B virus infection: A retrospective cohort study

High serum growth differentiation factor 15 is a risk factor for the occurrence of hepatocellular carcinoma in chronic hepatitis B patients treated with nucleos(t)ide analogs

432 TRANSFER OF HEPATITIS B SURFACE MARKERS AND HBVDNA FROM HEPATITIS B SURFACE ANTIGEN POSITIVE MOTHERS TO THEIR OFFSPRING

Quantitative anti-HBc combined with quantitative HBsAg can predict HBsAg clearance in sequential combination therapy with PEG-IFN-α in NA-suppressed chronic hepatitis B patients

HBsAg ≤ 135 IU/mL or HBcrAg ≤ 3.6 logU/mL was associated with HBsAg loss after nucleos(t)ide analogue cessation

Hepatitis B Virus Pregenomic RNA Status Can Reveal the Long‐term Prognoses of Chronic Hepatitis B Patients Treated with Nucleos(t)ide Analogues

Effect of nucleos(t)ide analogue discontinuation on the prognosis of HBeAg-negative hepatitis B virus-related hepatocellular carcinoma after hepatectomy: A propensity score matching analysis

Randomized Clinical Trial: Nucleos(t)ide Analogues Improved Survival of CHB-related HCC Patients Via Reducing Severity and Progression of Malignancy

Persistently high HBsAg levels during HBeAg‐seropositive stage predict lower risk of hepatocellular carcinoma in chronic hepatitis B patients